OncoTherapy Science, Inc. (TYO:4564)

OncoTherapy Science Revenue

OncoTherapy Science had revenue of 170.00M JPY in the quarter ending June 30, 2026, a decrease of -15.42%. This brings the company's total for the last twelve months to 777.00M, down -8.70% year-over-year. In the fiscal year ending March 31, 2026, OncoTherapy Science had annual revenue of 808.00M with 7.73% growth. That makes OncoTherapy Science the 40,027th largest company in the world by revenue and 3,811th in Japan.

• Revenue (ttm): 777.00M
• Revenue Growth: -8.70%
• P/S Ratio: 9.46
• Revenue / Employee: 16.89M
• Employees: 46
• Market Cap: 6.94B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Cancer Precision Medicine Related Business 806.20M 99.7%
• Pharmaceutical Research and Development and Related Businesses 2.64M 0.3%

Fiscal year ended Mar 31, 2026 See the full OncoTherapy Science breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	808.00M	58.00M	7.73%
Mar 31, 2025	750.00M	140.00M	22.95%
Mar 31, 2024	610.00M	-524.00M	-46.21%
Mar 31, 2023	1.13B	-19.00M	-1.65%
Mar 31, 2022	1.15B	821.00M	247.29%

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error